Anixa Biosciences (NASDAQ:ANIX) Now Covered by Maxim Group

Maxim Group began coverage on shares of Anixa Biosciences (NASDAQ:ANIX) in a research report released on Friday morning, MarketBeat.com reports. The firm issued a buy rating and a $10.00 target price on the stock.

Several other research analysts also recently commented on the company. D. Boral Capital reiterated a “buy” rating and issued a $10.00 price objective on shares of Anixa Biosciences in a report on Wednesday, January 22nd. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Anixa Biosciences in a research note on Tuesday, February 18th.

Anixa Biosciences Trading Up 0.3 %

ANIX opened at $3.16 on Friday. The company has a market cap of $101.74 million, a P/E ratio of -8.10 and a beta of 0.86. The business’s 50-day moving average price is $2.89 and its 200-day moving average price is $3.01. Anixa Biosciences has a 12 month low of $2.07 and a 12 month high of $4.20.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.10) EPS for the quarter, hitting the consensus estimate of ($0.10). Equities research analysts forecast that Anixa Biosciences will post -0.41 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Amit Kumar acquired 43,000 shares of the business’s stock in a transaction on Wednesday, January 15th. The shares were acquired at an average cost of $2.23 per share, with a total value of $95,890.00. Following the transaction, the chief executive officer now owns 559,925 shares in the company, valued at $1,248,632.75. The trade was a 8.32 % increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Lewis H. Titterton, Jr. acquired 10,000 shares of the business’s stock in a transaction on Friday, January 17th. The shares were purchased at an average cost of $2.57 per share, for a total transaction of $25,700.00. Following the completion of the transaction, the director now owns 922,334 shares in the company, valued at approximately $2,370,398.38. This represents a 1.10 % increase in their position. The disclosure for this purchase can be found here. Insiders have acquired 75,289 shares of company stock valued at $177,021 over the last ninety days. 25.30% of the stock is owned by insiders.

Institutional Trading of Anixa Biosciences

Large investors have recently bought and sold shares of the company. Millennium Management LLC bought a new stake in Anixa Biosciences during the 4th quarter valued at approximately $26,000. Virtu Financial LLC bought a new stake in shares of Anixa Biosciences in the 3rd quarter worth approximately $34,000. Renaissance Technologies LLC boosted its position in shares of Anixa Biosciences by 36.5% in the 4th quarter. Renaissance Technologies LLC now owns 14,573 shares of the company’s stock worth $34,000 after purchasing an additional 3,900 shares in the last quarter. Prosperity Wealth Management Inc. bought a new stake in shares of Anixa Biosciences in the 4th quarter worth approximately $54,000. Finally, Jane Street Group LLC bought a new stake in shares of Anixa Biosciences in the 4th quarter worth approximately $67,000. 29.13% of the stock is owned by institutional investors.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.